A citation-based method for searching scientific literature

Matthew J During, Lei Cao, David S Zuzga, Jeremy S Francis, Helen L Fitzsimons, Xiangyang Jiao, Ross J Bland, Matthias Klugmann, William A Banks, Daniel J Drucker, Colin N Haile. Nat Med 2003
Times Cited: 590







List of co-cited articles
1211 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölscher. J Neurosci 2011
469
31

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.
Simon C Cork, James E Richards, Marie K Holt, Fiona M Gribble, Frank Reimann, Stefan Trapp. Mol Metab 2015
224
24

Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
387
22

In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
Michael Gejl, Albert Gjedde, Lærke Egefjord, Arne Møller, Søren B Hansen, Kim Vang, Anders Rodell, Hans Brændgaard, Hanne Gottrup, Anna Schacht,[...]. Front Aging Neurosci 2016
208
20

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
405
20


The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test.
Ruben Isacson, Elisabet Nielsen, Karin Dannaeus, Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Lilian Wikström. Eur J Pharmacol 2011
101
16


Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
TracyAnn Perry, Norman J Haughey, Mark P Mattson, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
264
16


Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
342
14

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
241
14

The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem.
Elvira Alvarez, M Dolores Martínez, Isabel Roncero, Julie A Chowen, Beatriz García-Cuartero, Juan D Gispert, Carmen Sanz, Patricia Vázquez, Antonio Maldonado, Javier de Cáceres,[...]. J Neurochem 2005
177
14

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Grazia Daniela Femminella, Eleni Frangou, Sharon B Love, Gail Busza, Clive Holmes, Craig Ritchie, Robert Lawrence, Brady McFarlane, George Tadros, Basil H Ridha,[...]. Trials 2019
71
18



Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
12

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.
Yazhou Li, Kara B Duffy, Mary Ann Ottinger, Balmiki Ray, Jason A Bailey, Harold W Holloway, David Tweedie, Tracyann Perry, Mark P Mattson, Dimitrios Kapogiannis,[...]. J Alzheimers Dis 2010
229
12

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.
Abba J Kastin, Victoria Akerstrom, Weihong Pan. J Mol Neurosci 2002
344
12

GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality.
Rozita H Anderberg, Jennifer E Richard, Caroline Hansson, Hans Nissbrandt, Filip Bergquist, Karolina P Skibicka. Psychoneuroendocrinology 2016
71
15

Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
281
11

The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.
Andre F Batista, Leticia Forny-Germano, Julia R Clarke, Natalia M Lyra E Silva, Jordano Brito-Moreira, Susan E Boehnke, Andrew Winterborn, Brian C Coe, Ann Lablans, Juliana F Vital,[...]. J Pathol 2018
125
11

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.
Seung Pil Yun, Tae-In Kam, Nikhil Panicker, SangMin Kim, Yumin Oh, Jong-Sung Park, Seung-Hwan Kwon, Yong Joo Park, Senthilkumar S Karuppagounder, Hyejin Park,[...]. Nat Med 2018
415
11

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.
Steven E Arnold, Zoe Arvanitakis, Shannon L Macauley-Rambach, Aaron M Koenig, Hoau-Yan Wang, Rexford S Ahima, Suzanne Craft, Sam Gandy, Christoph Buettner, Luke E Stoeckel,[...]. Nat Rev Neurol 2018
513
11

A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
11



Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
Konrad Talbot, Hoau-Yan Wang, Hala Kazi, Li-Ying Han, Kalindi P Bakshi, Andres Stucky, Robert L Fuino, Krista R Kawaguchi, Andrew J Samoyedny, Robert S Wilson,[...]. J Clin Invest 2012
11

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
Theresa R Bomfim, Leticia Forny-Germano, Luciana B Sathler, Jordano Brito-Moreira, Jean-Christophe Houzel, Helena Decker, Michael A Silverman, Hala Kazi, Helen M Melo, Paula L McClean,[...]. J Clin Invest 2012
579
11

Entry of exendin-4 into brain is rapid but may be limited at high doses.
A J Kastin, V Akerstrom. Int J Obes Relat Metab Disord 2003
255
11


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
10

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.
TracyAnn Perry, Harold W Holloway, Ananda Weerasuriya, Peter R Mouton, Kara Duffy, Julie A Mattison, Nigel H Greig. Exp Neurol 2007
153
10

Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
Suzanne Craft, Laura D Baker, Thomas J Montine, Satoshi Minoshima, G Stennis Watson, Amy Claxton, Matthew Arbuckle, Maureen Callaghan, Elaine Tsai, Stephen R Plymate,[...]. Arch Neurol 2012
827
10

Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.
Kristy M Heppner, Melissa Kirigiti, Anna Secher, Sarah Juel Paulsen, Rikley Buckingham, Charles Pyke, Lotte B Knudsen, Niels Vrang, Kevin L Grove. Endocrinology 2015
105
10

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
Anna Secher, Jacob Jelsing, Arian F Baquero, Jacob Hecksher-Sørensen, Michael A Cowley, Louise S Dalbøge, Gitte Hansen, Kevin L Grove, Charles Pyke, Kirsten Raun,[...]. J Clin Invest 2014
426
10

A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
TracyAnn Perry, Debomoy K Lahiri, Demao Chen, Jie Zhou, Karen T Y Shaw, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
233
10

Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease.
Kathleen T Watson, Tonita E Wroolie, Gabby Tong, Lara C Foland-Ross, Sophia Frangou, Manpreet Singh, Roger S McIntyre, Siena Roat-Shumway, Alison Myoraku, Allan L Reiss,[...]. Behav Brain Res 2019
43
23

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
817
10


Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain.
A Hamilton, S Patterson, D Porter, V A Gault, C Holscher. J Neurosci Res 2011
152
9


GLP-1 and weight loss: unraveling the diverse neural circuitry.
Scott E Kanoski, Matthew R Hayes, Karolina P Skibicka. Am J Physiol Regul Integr Comp Physiol 2016
117
9

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.
Paul Richards, Helen E Parker, Alice E Adriaenssens, Joshua M Hodgson, Simon C Cork, Stefan Trapp, Fiona M Gribble, Frank Reimann. Diabetes 2014
276
9

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
9


GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Olivia M Farr, Michail Sofopoulos, Michael A Tsoukas, Fadime Dincer, Bindiya Thakkar, Ayse Sahin-Efe, Andreas Filippaios, Jennifer Bowers, Alexandra Srnka, Anna Gavrieli,[...]. Diabetologia 2016
119
8

Prevention of pentylenetetrazole-induced kindling and behavioral comorbidities in mice by levetiracetam combined with the GLP-1 agonist liraglutide: Involvement of brain antioxidant and BDNF upregulating properties.
Alana Gomes de Souza, Adriano José Maia Chaves Filho, João Victor Souza Oliveira, Denia Alves Albuquerque de Souza, Iardja Stéfane Lopes, Michele Albuquerque Jales de Carvalho, Klistenes Alves de Lima, Francisca Cléa Florenço Sousa, Silvânia Maria Mendes Vasconcelos, Danielle Macedo,[...]. Biomed Pharmacother 2019
38
21


The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors.
Suzanne L Dickson, Rozita H Shirazi, Caroline Hansson, Filip Bergquist, Hans Nissbrandt, Karolina P Skibicka. J Neurosci 2012
238
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.